Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 03, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 577 | $9.75 | 799,295 | |
| May 02, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 576 | $10.27 | 36,800 | |
| Feb 28, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 561 | $10.47 | 44,805 | |
| Jan 02, 2020 | Principal Accounting Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 553 | $9.55 | 20,489 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 550 | -- | -- | |
| Feb 22, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 550 | $9.94 | 708,431 | |
| Feb 22, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 550 | $9.94 | 708,431 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 548 | $11.00 | 42,818 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 543 | -- | -- | |
| Mar 25, 2009 | Sr VP, Technical Operations | Open market or private sale of non-derivative or derivative security | Form 4 | 531 | $10.00 | 44,040 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.